Divaya Bhutani, MD

Hematology
Internal Medicine, Medical Oncology
Accepting New Patients
Virtual Visits/Telehealth

On the web

Profile Headshot

Profile Navigation

Overview

Divaya Bhutani, MD, is a world-leading expert in multiple myeloma therapies and treatment strategies whose work in this field has been extensively published. As a hematologist and oncologist at NewYork-Presbyterian Lawrence Hospital, he specializes in cancer care, blood disorders, and benign hematology. He also serves as an assistant professor of medicine at Columbia University Irving Medical Center.

As an expert in myeloma, Dr. Bhutani is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. A well-respected and accomplished researcher, Dr. Bhutani has presented his work at at annual medical meetings of the American Society of Hematology and has been featured in medical journals, including Pharmacology & Therapeutics and Journal of Clinical Oncology.

Dr. Divaya Bhutani graduated from Govt. Medical College, Patiala in India. He did his Internal medicine residency at Mount Sinai School of Medicine, Bronx, NY and fellowship in Hematology and Oncology at Wayne State University and Karmanos Cancer Institute, Detroit. His prior experience includes work as an Attending Physician at Myeloma Institute of Research and Therapy at University of Arkansas for Medical Sciences, Little Rock, AR and Karmanos Cancer Institute, Wayne State University, Detroit. MI.

Academic Appointments

  • Associate Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

Existing Patients:
(646) 317-4805
New Patients:
(212) 305-5098

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199
  • NYP Employee Plan

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

RiverSpring

  • Special Needs

UnitedHealthcare

  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

World Trade Center Health Plan

  • World Trade Center Health Plan

*Before your appointment, please contact the doctor’s office or your insurance provider to verify that your insurance is accepted. This list of insurances can change, and the insurance plans listed may not be accepted at all office locations for this provider.

Credentials & Experience

Education & Training

  • Government Medical College - India
  • Internship: James J. Peters VA Medical Center
  • Residency: James J. Peters VA Medical Center
  • Fellowship: Karmanos Cancer Institute, Wayne State University

Committees, Societies, Councils

  • The American Society of Clinical Oncology
  • The American Society of Hematology
  • The American Society for Blood and Marrow Transplantation

Board Certifications

  • Hematology
  • Internal Medicine
  • Medical Oncology

Research

Dr. Bhutani’s research is in the development of novel therapies for Multiple Myeloma and studying the complications of stem cell transplantation. Dr. Bhutani has published multiple original articles in peer reviewed journals and presented his work at national meetings including American Society of Hematology and American Society of Clinical Oncology. While at Karmanos Cancer Institute, Dr. Bhutani received a grant to conduct an investigator initiated prospective trial studying, Selinexor in patients with Non-Hodgkin’s Lymphoma and an American Cancer Society grant to study the role of B lymphocytes in acute graft versus host disease. Currently, Dr. Bhutani is conducting two investigator initiated prospective clinical trials at Herbert Irving Comprehensive Cancer Center. One of the trials is evaluating the use of CD38 antibody (Isatuximab) in patients with Monoclonal Gammopathy of Renal Significance. The second trial is going to evaluate the use of Isatuximab to alter immune microenvironment in patients undergoing autologous stem cell transplantation for Multiple Myeloma or Lymphoma.

Dr. Bhutani is an active member of national cooperative group called Southwest Oncology Group (SWOG). Through SWOG, he is a principal investigator on a prospective trial (S2005) evaluating the use of Venetoclax in patients with Waldenstrom’s Macroglobulinemia. In addition, he is currently developing a trial trough SWOG, using anti-amyloid antibody CAEL-101 in patients with renal AL Amyloidosis.

Selected Publications

  1. Edwards CV, Rao N, Bhutani D, Mapara MY, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b Study of Monoclonal Antibody CAEL-101 (11-1F4) in Patients with AL Amyloidosis. Blood. 2021.
  2. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P,Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AD, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak W, Kwok F,  Shimazaki C, Kim JS, Crusoe E,  Ahmadi T, Tran N, Qin X, Vasey SV, Tromp B, Schecter JM, Weiss BM, huang SH, Vermeulen J, Merlini G, Comenzo RL for the ANDROMEDA Trial Investigators. Daratumumab-based Treatment for Immunoglobulin Light Chain Amyloidosis.  N Engl J Med. 2021 Jul 1;385(1):46-58.
  3. Coltoff A, Bomback A, Shirazian S, Lentzsch S, Bhutani D. Treatment of monoclonal gammopathy associated C3 glomerulopathy with daratumumab-based therapy. Clin Lymphoma Myeloma Leuk. 2021 Apr 23:S2152-2650(21)00155-5.
  4. Bhutani D, Pan S, Latif D, Goldsmith RL, Saith SE, Mapara MY, Chakraborty R, Lentzsch S , Maurer MS. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis. Clin Lymphoma Myeloma Leuk. 2021 Apr 23:S2152-2650(21)00154-3.
  5. Seymour EK, Khan HY, Li Y, Chaker M, Muqbil I, Aboukameel A, Ramchandren R, Houde C, Sterbis G, Yang J, Bhutani D, Pregja S, Reichel K, Huddlestun A, Neveux C, Corona K, Landesman Y, Shah J, Kauffman M, Shacham S, Mohammad RM, Azmi AS, Zonder JA. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. Clin Cancer Res. 2021 Jun 15;27(12):3307-3316. PMID: 33785483.
  6. Premkumar V, Pan S, Lentzsch S, Bhutani D. Use of Daratumumab in high risk Multiple Myeloma: A meta-analysis. eJHaem. 2020;1:267-271.
  7. Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P. Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. Bone Marrow Transplant. 2019 Jan;54(1):164-167.
  8. Bhutani D, Gregory Dyson, Richard Manasa, Abhinav Deol, Voravit Ratanatharathorn, Lois Ayash, Muneer Abidi, Lawrence G. Lum, Uberti Joseph. Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64.

For a complete list of publications, please visit PubMed.gov